Of consents and CONSORTS: Reporting ethics, law, and human rights in RCTs involving monitored overdose of healthy volunteers pre and post the "consort" guidelines

Journal of Toxicology - Clinical Toxicology

Volumn 41, Issue 2, 2003, Pages 93-99

  Faunce, Thomas A ^a   Buckley, Nicholas A ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

CONSORT; Ethics; Overdose; RCTs; Volunteers

Indexed keywords

ACTIVATED CARBON;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOCTOR PATIENT RELATION; DOCUMENTATION; DRUG OVERDOSE; ETHICS; HUMAN; HUMAN RIGHTS; INFORMED CONSENT; LAW; MONITORING; MOTIVATION; NORMAL HUMAN; PERSUASIVE COMMUNICATION; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ANTIDOTES; CHARCOAL; GUIDELINES; HELSINKI DECLARATION; HUMAN RIGHTS; HUMANS; MEDLINE; OVERDOSE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037278668     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120019120     Document Type: Article

References (39)

1. Meulenbelt J, Mensingam TT, Kortboyer JM, Speijers GJ, de Vries I. Healthy volunteer studies in toxicology. Toxicol Lett 1998; 102-103: 35-39.
2. McBride G. Phase one trials can exploit terminally ill patients. Br Med J 1994, 308 (6930): 679-680.
3. Steinbrook R. Improving protection for research subjects. N Engl J Med 2002, 346 (18): 1425-1430.
4. Day RO, Chalmers DR, Williams KM, Campbell TJ. The death of a healthy volunteer in a human research project: implications for Australian clinical research. Med J Aust 1998, 168 (9): 449-451.
5. Shalala D. Protecting research subjects-what must be done. N Engl J Med 2000, 343 (11): 808-810.
6. CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002.
7. Boyd R. A view from the man in the seat opposite. Br Med J 1998, 317 (7155): 410.
8. Lumley CE, Parkinson C, Walker SR. An international appraisal of the minimum duration of chronic animal toxicity studies. Hum Exp Toxicol 1992, 11 (3): 155-162.
9. Ryffel B. Unanticipated human toxicology of recombinant proteins. Arch. Toxicol. Suppl 1996, 18, 333-341.
10. Wager E, Tooley PJ, Emanuel MB, Wood SF. How to do it. Get patients' consent to enter clinical trials. Br Med J 1995, 311 (7007): 734-737.
11. Kalb PE, Koehler KG. Legal issues in scientific research. J Am Med Assoc 2002, 287 (1): 85-91.
12. Ruiz-Canela M, Martinez-Gonzalez MA, Gomez-Gracia E, Fernandez-Crehuet J. Informed consent and approval by institutional review boards in published reports on clinical trials. N Engl J Med 1999, 340 (14): 1114-1115.
13. Bromhead HJ, Goodman NW. CONSORT statement on the reporting standards of clinical trials. Reporting of refusal of consent to take part in clinical trials is still poor. Br Med J 1997, 314 (7087): 1126-1127.
14. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J Am Med Assoc 1996, 276 (8): 637-639.
15. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Ann Intern Med 1994, 121 (11): 894-895.
16. A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. J Am Med Assoc 1994, 272 (24): 1926-1931.
17. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, GØtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134 (8): 663-694.
18. Davidoff F. News from the International Committee of Medical Journal Editors. Ann Intem. Med 2000, 133 (3): 229-231.
19. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. J Am Med Assoc 2001, 285 (15): 1992-1995.
20. International Conference on Harmonisation Good Clinical Practice (ICHGCP). Guidelines for Good Clinical Practice. In: Foster C, ed. Manual for Research Ethics Committees. 5th ed. London: Kings College; 1997, p. 1-30.
21. McNamara RM, Aaron CK, Gemborys M, Davidheiser S. Efficacy of charcoal cathartic versus ipecac in reducing serum acetaminophen in a simulated overdose. Ann Emerg Med 1989, 18 (9): 934-938.
22. Eisen TF, Grbcich PA, Lacouture PG, Shannon MW, Woolf A. The adsorption of salicylates by a milk chocolate-charcoal mixture. Ann Emerg Med 1991, 20 (2): 143-146.
23. Keller RE, Schwab RA, Krenzelok EP. Contribution of sorbitol combined with activated charcoal in prevention of salicylate absorption. Ann Emerg Med 1990, 19 (6): 654-656.
24. Dillon EC, Jr. Wilton JH, Barlow JC, Watson WA. Large surface area activated charcoal and the inhibition of aspirin absorption. Ann Emerg Med 1989, 18 (5): 547-552.
25. Remmert HP, Olling M, Slob W, van der Giesen WF, van Dijk A, et al. Comparative antidotal efficacy of activated charcoal tablets, capsules and suspension in healthy volunteers. Eur J Clin Pharmacol 1990, 39 (5): 501-505.
26. Rose SR, Gorman RL, Oderda GM, Klein-Schwartz W, Watson WA. Simulated acetaminophen overdose: pharmacokinetics and effectiveness of activated charcoal. Ann Emerg Med 1991, 20 (10): 1064-1068.
27. Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989, 46 (3): 264-271.
28. Yeates PJ, Thomas SH. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. Br J Clin Pharmacol 2000, 49 (1): 11-14.
29. Lapatto-Reiniluoto O, Kivisto KT, Neuvonen PJ. Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. Br J Clin Pharmacol 1999, 48 (2): 148-153.
30. Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol 2001, 39 (6): 601-605.
31. Rangan C, Nordt SP, Hamilton R, Ingels M, Clark RF. Treatment of acetaminophen ingestion with a super-activated charcoal-cola mixture. Ann Emerg Med 2001, 37 (1): 55-58.
32. Elomaa K, Ranta S, Tuominen J, Lahteenmaki P. Charcoal treatment and risk of escape ovulation in oral contraceptive users. Hum Reprod 2001, 16 (1): 76-81.
33. Orisakwe OE, Ilondu ND, Afonne OJ, Ofoefule SI, Orish CN, Agbasi PU. Effect of activated charcoal on diethylcarbamazine absorption in humans. Am J Ther 2001, 8 (1): 7-9.
34. Savulescu J. Commentary: safety of participants in non-therapeutic research must be ensured. Br Med J 1998, 316 (7135): 891-892.
35. Skene L, Smallwood R. Informed consent: lessons from Australia. Br Med J 2002, 324 (7328): 39-41.
36. Yank V, Rennie D. Reporting of informed consent and ethics committee approval in clinical trials. J Am Med Assoc 2002, 287 (21): 2835-2838.
37. Steinbrook R. Protecting research subjects - the crisis at Johns Hopkins. N Engl J Med 2002, 346 (9): 716-720.
38. Christian MC, Goldberg JL, Killen J, Abrams JS, McCabe MS, Mauer JK, et al. A central institutional review board for multi-institutional trials. N Engl J Med 2002, 346 (18): 1405-1408.
39. Miller FG, Rosenstein DL. Reporting of ethical issues in publications of medical research. Lancet 2002, 360, 1326-1328.